New drug plozasiran reduces triglyceride levels and cardiovascular risk for mixed hyperlipidemia patients in Phase 2b MUIR trial.

New drug plozasiran shows promise in reducing triglyceride levels and cardiovascular risk for individuals with mixed hyperlipidemia. The treatment targets ApoC3, a key regulator of lipoprotein particles carrying triglyceride and cholesterol remnants. Phase 2b, double-blind, randomized MUIR trial results, published in the New England Journal of Medicine, demonstrate the drug's effectiveness.